Special Issue "Clinical Application of Botulinum Toxin"

A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Bacterial Toxins".

Deadline for manuscript submissions: 31 January 2022.

Special Issue Editor

Prof. Dr. Markus Naumann
Guest Editor
Department of Neurology and Clinical Neurophysiology, Academic Hospital, Klinikum Augsburg, Augsburg 86156, Germany
Interests: movement disorders; botulinum toxin; autonomic disorders; neurophysiology; neuroimaging
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Botulinum toxin has been approved for many disorders, including movement disorders, autonomic disorders (i.e., secretory, bladder), pain, and ophthalmologic uses. Among movement disorders, it has revolutionized the treatment of focal spasticity of upper and lower limbs, focal dystonias, and some other rare conditions. In spasticity and dystonia, the mode of action of botulinum toxin is complex and is not only based on a blockage of acetylcholine release at the neuromuscular junction, leading to muscle weakness. Due to its effect on muscle spindles, it exerts an additional effect on different pathways to the central nervous system, thereby markedly contributing to beneficial clinical effects. There is increasing evidence that treatment outcomes can be optimized using guided injection techniques.

The focus of this Special Issue of Toxins will be on botulinum toxin treatment of movement disorders, in all its aspects: Treatment outcomes in focal spasticity, dystonias, tremors, and other movement disorders; effects of different serotypes; dosing and side effects; antigenicity; evidence-based medicine; guided injection techniques (ultrasound, EMG, stimulation, imaging); sensorimotor aspects of mode of action; and others.

Prof. Dr. Markus Naumann
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • botulinum toxin
  • spasticity
  • dystonia
  • mode of action
  • guidance
  • outcome
  • clinic therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Lantox—The Chinese Botulinum Toxin Drug—Complete English Bibliography and Comprehensive Formalised Literature Review
Toxins 2021, 13(6), 370; https://0-doi-org.brum.beds.ac.uk/10.3390/toxins13060370 - 22 May 2021
Viewed by 918
In 1997, lanbotulinumtoxinA (LAN) was introduced in China. It is now available in Asia, Latin America and Eastern Europe under various brand names including Hengli®, Lantox®, Prosigne®, Lanzox®, Redux®, Liftox®, HBTX-A [...] Read more.
In 1997, lanbotulinumtoxinA (LAN) was introduced in China. It is now available in Asia, Latin America and Eastern Europe under various brand names including Hengli®, Lantox®, Prosigne®, Lanzox®, Redux®, Liftox®, HBTX-A and CBTX-A. The literature on LAN is mostly published in Chinese language, restricting its international accessibility. We, therefore, wanted to generate a complete English bibliography of all LAN publications and then use it for a comprehensive formalised literature review. Altogether, 379 LAN publications (322 in Chinese and 57 in English) were retrieved from PubMed and Science and Technology Paper Citation Database. Indications covered are motor (257), glandular (16), pain (32) and aesthetics (48). Topics are neurological (250), aesthetic (48), paediatric (38), ophthalmological (18), urological (9), methodological (6), gastroenterological (5), ear, nose and throat (4) and surgical (1). Seventy-one publications are randomised controlled trials, forty-one publications are interventional studies and observational studies, fifteen publications are case studies, eighteen publications are reviews, and two publications are guidelines. LAN publications cover all relevant topics of BT therapy throughout a period of more than 20 years. This constitutes a publication basis resembling those of other BT drugs. None of the LAN publications presents data contradictory to those generated with other BT type-A drugs. LAN seems to have a similar efficacy and safety features when compared to onabotulinumtoxinA using a 1:1 LAN– onabotulinumtoxinA conversion ratio. Large controlled multicentre studies will become necessary for LAN’s registrations in Europe and North America. Full article
(This article belongs to the Special Issue Clinical Application of Botulinum Toxin)
Back to TopTop